TaiMed Biologics press release
TAIPEI, May 21, 2026 — TaiMed Biologics (TPEX: 4147) today announced the completion of enrollment in its Phase 2b clinical study evaluating TMB-365/380, a novel investigational long-acting dual-antibody regimen for HIV maintenance therapy. The study reached Last Patient In (LPI) ahead of the planned schedule, marking an important operational milestone for the program.
The Phase 2b study is designed to evaluate the efficacy and safety of TMB-365/380 as an every-two-month (Q2M), first-line HIV maintenance therapy for people living with HIV. With enrollment now complete, participants will continue scheduled follow-up, and TaiMed expects to report an interim analysis by year-end 2026. The Company believes the interim readout may help inform subsequent development and regulatory planning. Preliminary observations from ongoing follow-up show that viral suppression and relevant biomarkers following the first two doses are fully consistent with the Company’s expectations.
Subject to continued positive outcomes, the Company plans to submit a Breakthrough Therapy Designation application to the U.S. Food and Drug Administration (FDA).
Read the full press release here.
Source : TaiMed Biologics
Related HIV and Co-Infections News
-
Spotlight: South Africa’s ARV programme hardly grew in 2025, according to latest estimates
-
[Press release] ViiV Healthcare aims to close treatment gaps for children living with HIV with paediatric Dovato marketing applications to the EMA and FDA
-
Infectious Disease Advisor: Dolutegravir plus lamivudine maintains HIV-1 suppression without HBV reactivation
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.